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Abstract
Background: The aim of this study was to compare 64Cu-diacetyl-bis(N4-methylsemicarbazone) (64Cu-ATSM) and
18FDG PET uptake characteristics and 64Cu-ATSM autoradiography to pimonidazole immunohistochemistry in
spontaneous canine sarcomas and carcinomas.
Methods: Biopsies were collected from individual tumors between approximately 3 and 25 hours after the
intravenous injection of 64Cu-ATSM and pimonidazole. 64Cu-ATSM autoradiography and pimonidazole
immunostaining was performed on sectioned biopsies. Acquired 64Cu-ATSM autoradiography and pimonidazole
images were rescaled, aligned and their distribution patterns compared. 64Cu-ATSM and 18FDG PET/CT scans were
performed in a concurrent study and uptake characteristics were obtained for tumors where available.
Results: Maximum pimonidazole pixel value and mean pimonidazole labeled fraction was found to be strongly
correlated to 18FDG PET uptake levels, whereas more varying results were obtained for the comparison to 64Cu-
ATSM. In the case of the latter, uptake at scans performed 3 h post injection (pi) generally showed strong positive
correlated to pimonidazole uptake.
Comparison of distribution patterns of pimonidazole immunohistochemistry and 64Cu-ATSM autoradiography
yielded varying results. Significant positive correlations were mainly found in sections displaying a heterogeneous
distribution of tracers.
Conclusions: Tumors with high levels of pimonidazole staining generally displayed high uptake of 18FDG and 64Cu-
ATSM (3 h pi.). Similar regional distribution of 64Cu-ATSM and pimonidazole was observed in most heterogeneous
tumor regions. However, tumor and hypoxia level dependent differences may exist with regard to the hypoxia
specificity of 64Cu-ATSM in canine tumors.
Background
The presence of hypoxic regions within solid tumors
was recognized more than 50 years ago [1]. Hypoxic
cancer cells are inherently resistant to treatment and the
hostile microenvironment associated with them exerts a
selective pressure that causes proteomic and genetic
changes, which increase tumor aggressiveness [2,3].
Tumor hypoxia effects therapeutic outcome so diag-
nostic modalities that can identify hypoxia will benefit
patients by stratifying for hypoxia adapted treatment.
Several methodologies for the assessment of tumor hyp-
oxia have been investigated, including positron emission
tomography (PET). Hypoxia specific radiotracers, mostly
2-nitroimidazole derivates, such as 18 F-Fluoromisonida-
zole (F-MISO) are the most intensely studied [4-6]. Des-
pite the generally positive correlation between the
uptake of 2-nitroimidazoles and that of other hypoxic
markers, their kinetics, slow hypoxia-specific retention
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and slow clearance of non-bound contaminating tracer
are problematic [6]. Cu-diacetyl-bis(N4-methylsemicar-
bazone) (Cu-ATSM) is among the most promising alter-
natives to 2-nitroimidazole for hypoxia PET imaging.
Cu-ATSM is a highly membrane permeable complex
with a rapid blood clearance and high intertissue and
intratumoral contrast. The proposed trapping mechan-
ism of Cu-ATSM is indirectly linked to hypoxia, via
chemical reduction from a cell membrane permeable to
a non-permeable state. The exact mechanism by which
Cu-ATSM is trapped in hypoxic cells or the oxygen-level
required for accumulation is however not completely
understood [7,8].
Invasive and non-invasive preclinical studies of Cu-
ATSM have been conducted in xenografted animal mod-
els using various cancer lines. Cu-ATSM accumulation
was positively correlated to hypoxia as measured by po-
larographic microelectrodes in a 9 L gliosarcoma rat
model [9]. Additional studies have examined the uptake
and distribution patterns of Cu-ATSM, to various non-
invasive and invasive surrogate markers for hypoxia.
Conflicting results have been obtained in these studies,
which have questioned the universal hypoxia selectivity
of the tracer and pointed towards potential tumor type
dependent differences in accumulation kinetics [10-13].
These pre-clinical studies have underlined the need for
additional invasive studies, preferably in a large spontan-
eous tumor model, to further investigate the distribution
and uptake kinetics of Cu-ATSM and thus its usefulness
as a non-invasive hypoxia radiotracer.
Pimonidazole belongs to the group of 2-
nitroimidazoles and is a cell permeable hypoxia marker
that is reduced and irreversibly trapped under hypoxic
conditions (pO2< 10 mmHg). Specific antibodies have
been developed that targets pimonidazole adducts
formed by nitroreductases under hypoxic conditions.
Immunohistochemical analysis of pimonidazole adduct
formations is therefore possible following systemic ad-
ministration of pimonidazole [14,15].
The objective of this study was to compare uptake
characteristics of pimonidazole immunohistochemistry
to 64Cu-ATSM autoradiography and to PET uptake
levels of 64Cu-ATSM and 2-deoxy-2-[18 F]fluoro-D-glu-
cose (18FDG) in spontaneous canine sarcomas and car-
cinomas. This study supplements previously reported
non-invasive findings using Cu-ATSM and FDG as PET
tracers in spontaneous canine tumors [16].
Methods
Study population
Spontaneous canine cancer patients with histologically
diagnosed soft tissue sarcomas or carcinomas were eli-
gible for inclusion. Owners of the dogs concerned pro-
vided written informed consent prior to inclusion in the
study. Eight dogs met the inclusion criteria of this study
(Table 1), dogs 1 to 6 also participated in a concurrent
study [16]. The study protocol was approved by the eth-
ical and administrative research committee at the De-
partment of Small Animal Clinical Sciences, Faculty of
Life Sciences, University of Copenhagen.
Experimental setup
PET/CT scans were performed using a combined PET/
CT scanner (Biograph 40, Siemens, Germany); consisting
of a high-resolution PET-scanner and a 40-slice CT-
scanner. CT parameters; slice thickness of 3.0 mm,
120 kV, 170 mAs, pitch 1.2, collimation 24 × 1.2 mm
and a B30 kernel. The PET scans were acquired using a
3D acquisition mode and a 3D OSEM reconstruction (4
iterations, 8 subsets), and smoothed using a Gaussian fil-
ter having a FWHM of 3 mm, and a matrix size of 256 ×
256. Tumor uptake of 64Cu-ATSM and 18FDG recorded
on the PET/CT scans were determined using commer-
cially available software (Pmod 3.0, Pmod Technologies,
Switzerland) and reported in Table 1. In short, tumor
volumes of interests (VOIs) were constructed manually
and mean and maximum uptake values of 64Cu-ATSM
and 18FDG determined. Muscle reference VOIs were
placed manually in 5 slices on tumor adjacent muscula-
ture. All images and VOIs were evaluated by an experi-
enced human PET physician and a board certified
veterinary radiologist. 18FDG uptake levels were calcu-
lated and reported as standardized uptake values (SUV)
and 64Cu-ATSM as tumor mean (Tmean) and tumor
maximum (Tmax) to muscle mean (Mmean) uptake ratios.
18FDG and 64Cu-ATSM PET/CT scans were per-
formed before any biopsy procedures.18FDG PET/CT
scans were performed on day 1 approximately 1 hour
after the injection of 18FDG (injected activity 6.0-
11.0 MBq/kg) and 64Cu-ATSM PET/CT scans were per-
formed on the following two days approximately 3 and
24 hours after the injection of 64Cu-ATSM (injected ac-
tivity 5.5 to 10.0 MBq/kg). Procedures performed on in-
dividual dogs are listed in table 1. Scanning and biopsy
routines were as follows. Dogs received 64Cu-ATSM
intravenously as a bolus. Ten to 30 min prior to this all
dogs received an intravenous injection of 0.5 g Pimoni-
dazole HCL/m2 body surface area suspended in 50 ml.
of isotonic saline solution in accordance with a previ-
ously published procedure [17]. For scanning and biopsy
procedures the dogs were pre-medicated with Metha-
done (0.2 to 0.3 mg/kg IM) and anesthetized using a
bolus injection of Propofol. They were provided with
100 % oxygen via an endotracheal tube. Anesthesia was
maintained by a continuous rate infusion of Propofol
(15–25 mg/kg/hr). Heart rate, oxygen saturation, CO2
concentrations, and blood pressure were monitored
throughout the procedures. Tumor biopsies were
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Table 1 Tumor characteristics













Cm3 Approx. 3 h. pi. Approx. 24 h. pi. Approx.1 h pi.
1a Fibrosarcoma 12.0 3.3 1.8 1.7 0.8 3.8 1.9 0.91 0.14
1b After 45 Gy. RT 9.5 3.2 1.8 1.6 0.8 1.5 0.9 0.55 0.01
2 Squamous cell carcinoma 14.4 7.4 4.2 4.0 2.3 11.8 5.5 0.91 0.13
3 Undiff. sarcoma 12.3 6.8 4.0 4.1 2.0 9.1 5.6 0.94 0.10
4 Hemangiopericytoma 79.9 3.1 1.9 2.5 1.5 3.4 1.7 0.85 0.03
5 Fibrosarcoma 72.2 6.4 2.5 7.1 1.6 6.8 3.2 0.70 0.03
6 Fibrosarcoma 70.4 6.6 3.5 5.8 2.4 7.6 5.1 1.00 0.09
7 Hemangiopericytoma 13.8 1.2 0.6 N/A N/A 2.7 1.3 0.55 0.03
8a Fibrosarcoma 138.5 1.5 0.8 N/A N/A 2.0 1.2 0.38 0.01
8b After 45 Gy. RT N/A N/A N/A N/A N/A N/A N/A 0.15 0.0

















collected approximately 25 hours after the injection of
Cu-ATSM in dogs 1 to 6. Biopsies from dog 7 where
collected 10 hours after injection of Cu-ATSM. Dog 1
and 8 had biopsies collected both before, designated 1a
and 8a, and after radiotherapy, designated 1b and 8b, re-
spectively. Biopsies from dog 8 were collected 14 hours
(8a) and 3 hours (8b) the injected of Cu-ATSM. Post
radiotherapy biopsies were collected 6 weeks after com-
pletion of 45 Gy. radiation therapy (10 fractions of
4.5 Gy, three weekly treatments).
From each tumor biopsy set, three to nine individual
biopsies, ranging from approximately 5 × 5 × 5 mm. to
10 × 10 × 10 mm. were collected from various regions
within the tumor by a sterile procedure. Biopsies were
snap-frozen in liquid nitrogen immediately after collec-
tion and subsequently several 10 μm sections were cut
from each using a cryostat and then thaw mounted on
poly-L-lysine coated microscopy slides.
Autoradiography
The spatial distribution pattern of 64Cu-ATSM was
determined by exposing tumor sections to phosphor im-
aging screens for 20 hours. These screens were read
using a phosphor imaging system (Cyclone Plus Phos-
phor Imager, Perkin Elmer, Waltham, MA., USA), to
form semi-quantitative photo-stimulated luminescence
images of 64Cu-ATSM micro regional distributions.
Tumor slides were subsequently frozen and stored at
−80 °C until immunohistochemical analysis.
Immunohistochemistry
Three to nine tumor sections from the individual tumors
were evaluated microscopically for the distribution of
bound pimonidazole. Immunohistochemical staining
was performed using a previously described method-
ology [18]. Stained tumor sections were analyzed using a
semiautomatic digital image acquisition system. Gray
value images with a pixel size of 2.67 × 2.67 μm showing
the distribution of pimonidazole were obtained and
transformed at the pixel level into segmented binary
images to visualize pimonidazole-positive cells using a
previously published method [18].
Image analysis
The spatial distribution patterns of 64Cu-ATSM photolu-
minescence autoradiography were compared to pimoni-
dazole on the individual tumor sections using ImageJ
(public domain, Java-based image processing program).
All images were manually aligned and then cropped,
based on masks drawn on pimonidazole immunofluores-
cence images to exclude areas of necrosis, dust particles
and tissue holes. Images were subsequently rescaled to
identical pixel sizes (100 × 100 μm), using pixel aver-
aging without image interpolation. Regions of interest
(ROIs) were manually drawn on pimonidazole immuno-
fluorescence images, excluding the peripheral pixels to
avoid influence of pixel averaging when downsizing.
Maximum pimonidazole labeled pixel value and mean
pimonidazole positive labeled area fraction was calcu-
lated from the rescaled 100 × 100 μm pixel images. The
pixel values on the rescaled on the 100 × 100 μm pixel
images is the fraction of pimonidazole positive 2.67 ×
2.67 μm pixels divided by the total number of 2.67 ×
2.67 μm binary pixels composing the rescaled 100 × 100
μm pixels. Maximum pimonidazole labeled pixel value
represent the single 100 × 100 μm pixel with the highest
fraction of 2.67 × 2.67 μm pimonidazole positive pixels
from all sections of the tumor. Mean pimonidazole posi-
tive labeled area fraction represent the average 100 ×
100 μm image pixel value of all sections from the indi-
vidual tumors.
Pimonidazole uptake characteristics of the individual
tumors was examined and correlated to tumor PET up-
take characteristics of 64Cu-ATSM and 18FDG from the
previously performed PET scans. Mean pimonidazole
positive area fraction and maximum pimonidazole pixel
values were correlated to maximum and mean tumor to
muscle uptake ratios of 64Cu-ATSM and maximum and
mean SUV of 18FDG.
The 100 × 100 μm pimonidazole immunofluorescence
and corresponding co-registered 100 × 100 μm 64Cu-
ATSM autoradiography images were rescaled to a pixel
size of 1 × 1 mm by pixel averaging without
interpolation. The two-step rescaling procedure allowed
for the recognition and exclusion of artifacts within both
immunohistochemical and autoradiography images at
similar resolution. The manual ROIs from original
images were applied to the 1 × 1 mm pixel size images
and only pixels not transversed by the section-
delineating ROI were included during subsequent pixel-
by-pixel correlation analysis (Figure 1).
Statistical analysis
Statistical analyses were performed using Graph Pad
Prism (Version 5.0b, GraphPad, Inc. La Jolla, Ca, USA).
All correlations were performed as non-parametric
Spearman’s rank correlation analysis. For all statistical
analysis a p-value< 0.05 was considered significant.
Results
Maximum pimonidazole labeled pixel value ranged from
1.0 to 0.15, while pimonidazole positive area fraction
ranged from 0.14 to 0.0 between tumors.
The 64Cu-ATSM Tmax/Mmean uptake ratio deduced
from images acquired 3 hours pi. was found to be posi-
tively correlated to maximum pixel value in pimonida-
zole labeled images with a correlation coefficient of 0.81
(p = 0.011), and to pimonidazole positive fractions by a
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correlation coefficient of 0.69 (p = 0.043). The 64Cu-
ATSM Tmean/Mmean uptake ratio at 3 hours pi. was also
significantly correlated to maximum pimonidazole pixel
values, by a correlation coefficient of 0.77 (p = 0.021).
Mean and maximum 18FDG SUV displayed a positive
correlation to pimonidazole staining values. Maximum
18FDG SUV was correlated to both pimonidazole max-
imum and pimonidazole positive area fraction values
with correlation coefficients of 0.82 (p = 0.008) and 0.79
(p = 0.014), respectively. Mean 18FDG SUV correlated to
maximum and mean pimonidazole pixel values with cor-
relation coefficients of 0.85 (p = 0.008) and 0.77
(p = 0.017), respectively. Correlation between 64Cu-
ATSM Tmean/Mmean 3 hours pi. and mean pimonidazole
positive area fraction and all correlations between 64Cu-
ATSM uptake 24 hours pi. and pimonidazole and were
found to be statistically insignificant (Table 2).
Pixel-by-pixel correlation analysis of 64Cu-ATSM auto-
radiography and pimonidazole immunofluorescence
yielded varying results with correlation coefficients of in-
dividual sections ranging from a strong positive correl-
ation of 0.88 to a moderate negative of −0.56). The
correlation coefficients were only statistically significant
in 15 out of 55 sections. Twelve sections displayed a sta-
tistically significant positive correlation, ranging from
0.41 to 0.88 and three sections from one tumor,
displayed a significant negative correlation ranging from
−0.35 to −0.56. Figure 2 illustrates two sections with
positive and no correlation, respectively. The sections
from the tumor of dog no.6 displayed the most statisti-
cally significant positive correlation, with significant cor-
relation coefficients ranging from 0.41 to 0.77 (mean
0.63) in six of nine evaluated sections.
Discussion
The observed correlations between 64Cu-ATSM PET up-
take and pimonidazole staining characteristics indicate
that high 64Cu-ATSM uptake on PET, at least at 3 hours
pi., is indicative of intratumoral hypoxia as measured by
pimonidazole immunostainings. The validity of comparing
Cu-ATSM PET uptake at 3 hours pi and pimonidazole
immunohistochemistry on biopsies collected up to 25
hours after administration can be discussed. Previous
studies on pimonidazole in canine tumors have reported
that adduct formation occurs from within 20 minutes and
sufficient antigen persists for days to allow for acceptable
immunohistochemistry [17]. This together with the pimo-
nidazole adduct formation being irreversible in hypoxic
cells and its relatively short plasma half-life [15,17], makes
a comparison of 3 hour Cu-ATSM PET and pimonidazole
valid. The lack of information on the reversibility of cellu-
lar Cu-ATSM binding justifies similar considerations for
Figure 1 Pixel-by-pixel correlation. Methodology for pixel-by-pixel correlation analysis of pimonidazole immunostainings and 64Cu-ATSM
autoradiography images. A, 100 × 100 μm pimonidazole image, with original ROI excluding folding and artifacts. B, 100 × 100 μm 64Cu-ATSM
autoradiography image, identical ROI as image A. C, 64Cu-ATSM image rescaled from a pixel size of 100 × 100 μm to 1×1 mm, identical ROI as
image A. D, new ROI applied with only pixels not transversed by the original ROI from image A included. Soft tissue sarcoma, displaying a weak
insignificant correlation (rs = 0.30, p-value: 0.12) between the two modalities.
Table 2 FDG and 64Cu-ATSM PET uptake vs. Pimonidazole staining
Maximum pimonidazole labeled pixel value Mean pimonidazole positive area fraction
64Cu-ATSM Tmax/Mmean 3 h. 0.81 (p= 0.011) 0.69 (p = 0.043)
64Cu-ATSM Tmean/Mmean 3 h. 0.77 (p= 0.021) 0.56 (p = 0.126)
64Cu-ATSM Tmax/Mmean 24 h. 0.40 (p = 0.396) 0.036 (p = 0.964)
64Cu-ATSM Tmean/Mmean 24 h. 0.70 (p = 0.088) 0.24 (p = 0.595)
18FDG SUVmax 0.82 (p= 0.008) 0.79 (p = 0.014)
18FDG SUVmean 0.85 (p= 0.008) 0.77 (p = 0.017)
Pimonidazole maximum labeled pixel value and mean pimonidazole positive area fraction of individual tumors correlated to their 64Cu-ATSM maximum and mean
T/M ratios 3 and 24 h. pi. and 18FDG maximum and mean SUV. Spearman non-parametric correlation coefficients and p-value. Significant correlations in bold.
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the comparison of Cu-ATSM PET 24 hour pi. uptake
characteristics and pimonidazole.
The maximum and mean SUV of 18FDG on PET
images displayed a strong positive correlation to pimoni-
dazole staining characteristics. Interestingly, based on
these correlations, 64Cu-ATSM tumor PET uptake
appears not to improve on 18FDG uptake as a hypoxia
marker where hypoxia is assessed by pimonidazole
immunohistochemistry on tumor biopsies. However, no
information on the spatial correlation between 18FDG
and pimonidazole was available.
The correlation between pimonidazole and uptake of
the two markers 18FDG and 64Cu-ATSM could indicate
that hypoxic tumors display increased glycolytic activity
(Pasteur effect) [19] or that highly glycolytic tumors
might have a more aggressive growth potential, which
increases the risk of forming hypoxic tumor regions
[20]. There are limitations in this interpretation given
the low number of tumors, the different histopatholo-
gies, and the potential for different baseline glycolytic ac-
tivity irrespective of hypoxia. Previous studies assessing
the potential of 18FDG as a surrogate marker of hypoxia
have reported similar concerns. [21].
The wide spectrum of correlations between 64Cu-
ATSM autoradiography and pimonidazole immunofluor-
escence is indicated by Spearman’s rank correlation coef-
ficients ranging from strong positive to moderate
negative from the individual tumor sections. A clear ten-
dency for increased positive correlation was observed in
tumors and sections displaying higher maximum and
mean pimonidazole labeling fractions. A negative correl-
ation between the two modalities was only observed for
one tumor, which suggests that potential tumor
dependent differences could exist.
The distribution of the two tracers in tumor sections
displaying a heterogeneous uptake patterns indicate that
64Cu-ATSM, at least in these sections, is an indicator of
regional tumor hypoxia as assessed by pimonidazole. No
firm conclusions into to the can be made on the data
reported here. Based on the different uptake mechan-
isms of Cu-ATSM and pimonidazole, including differ-
ences in oxygen levels required for induction and
maximal binding, a completely similar microregional
distribution can probably not be expected from the two
labels. The pimonidazole positive staining region on the
binary segmented images ranged from 0 to 0.14 between
tumors, which means that in the major part of sections,
the few scattered pimonidazole positive pixels seen were
likely the result of random noise and would not be
expected to have corresponding 64Cu-ATSM activity. In
contrast, regions displaying more intense activity, some
correlation was seen. In these higher uptake areas correl-
ation coefficients indicate that 64Cu-ATSM accumulates
in patterns that to some extent are comparable to those
of pimonidazole. However, despite this trend, one tumor
displayed a negative correlation between the two tracers,
which could be comparable to previous observation in
preclinical studies [10,11]. Cycling changes in hypoxia
distribution have been identified as a hallmark feature of
solid tumors [22]. Since pimonidazole adduct formation
is irreversible and if for the sake of argument Cu-ATSM
accumulation is reversible in cells experiencing re-
oxygenation then varying correlations observed between
Cu-ATSM 24 hours pi. and pimonidazole can be
explained. Pixel-by-pixel comparisons were performed at
a pixel size of 1 × 1 mm, which limits the possibility to
detect minor spatial differences between the two tracers.
However, the use of this pixel size decreases both image
noise and the influence of minor inaccuracies in the co-
registration process. It could be argued that a larger
pixel size would add additional information and better
mimic the resolution of modern PET scanners [23],
Figure 2 Pimonidazole immunofluorescence and 64Cu-ATSM autoradiography. Pimonidazole immunofluorescence (A and C) and
64Cu-ATSM photoluminescence autoradiography (B and D) of tumor sections from a fibrosarcoma (A and B) and an undifferentiated sarcoma
(C and D). The fibrosarcoma displayed high and heterogeneous pimonidazole immunofluorescence staining (A) whereas lower and more
homogeneous pimonidazole staining was found in the undifferentiated sarcoma (D). A strong correlation (rs = 0.72; p< 0.001) with
64Cu-ATSM
was found in the fibrosarcoma (A vs. B) whereas this was not the case in the undifferentiated sarcoma (C vs. D).
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however increasing pixel sizes beyond 1 × 1 mm was
not reasonable considering the sizes of tumor sections
used. Biopsies were for most tumors obtained after ap-
proximately 25 hours. The optimal period allowed for
the distribution of 64Cu-ATSM in spontaneous canine
tumors is not reported. It is possible that no general op-
timal period exists as based on previously reported find-
ings in xenografted models, the distribution period
necessary for 64Cu-ATSM to attain sufficient hypoxia-
specificity varies widely among tumors [11].
The tumor sections from biopsies obtained after
shorter distribution periods than approximately 25 hours
displayed no improved pimonidazole staining or 64Cu-
ATSM uptake or heterogeneity. These sections did how-
ever only display limited accumulation of both tracers
and more intensively staining sections could potentially
show a benefit with regard to earlier sampling time. We
have previously reported a delayed accumulation of Cu-
ATSM in hypoperfused tumor regions [16]. The tumor
of dog no. 6 was included in the previous study and dis-
played a central hypoperfused tumor core with delayed
accumulation of Cu-ATSM. Interestingly, six of nine
sections from this tumor displayed a statistically signifi-
cant moderate to strong positive correlation between
Cu-ATSM and pimonidazole after a distribution period
of 25 hours, indicating that, at least in this tumor, pro-
longed distribution periods for Cu-ATSM may be
required.
There are several limitations to this study, in particular
the low number of tumors investigated, their varying
histopathologies and the need for general anesthesia
during procedures. The validity of comparing universal
tumor uptake levels of 18FDG and 64Cu-ATSM, assessed
by PET imaging, to regional uptake levels on segmented
pimonidazole immunostainings is also questionable. Fur-
thermore, the microregional spatial comparison of two
different hypoxia markers with different uptake mechan-
isms and probably differences in oxygen level depend-
ence for accumulation, cannot be expected to be exactly
identical and directly comparable. Non-invasive and in-
vasive imaging studies of tumor hypoxia may addition-
ally be affected by long periods between injection of
tracers and image acquisition considering the varying
survival time and turn over of hypoxic tumor cells
reported [14].
Conclusions
In conclusion this study provides several indications that
64Cu-ATSM accumulation patterns are comparable to
those of pimonidazole in several spontaneous tumors
available in this study. It also suggests that the hypoxia
specificity of 64Cu-ATSM may differ between tumors
and with level of hypoxia.
Validation against invasive measures of hypoxia is im-
portant in the evaluation and development of non-
invasive alternatives. In this perspective spontaneous
clinical animal models hold the potential to bridge the
numerous gaps between pre-clinical induced cancer
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